GITG MASTERPLAN at #ESMO2026:
Adding SBRT to chemotherapy in pancreatic cancer reduced 12-month locoregional recurrence (20.2% vs 52.0%).
Median PFS: 11.9 vs 6.3 months.
Median OS: 22 vs 14 months.
Promising randomized results presented by Andrew Oar.
@myESMO
https://oncodaily.com/oncolibrary/radiotherapy/agitg-masterplan-trial
5 views · 0 likes · 0 reposts · 0 replies
TQB2102, a novel HER2 bispecific antibody-drug conjugate, combined with bemotrizumab with or without capecitabine as first-line therapy for HER2-positive advanced gastric/gastroesophageal junction cancer: A phase II study
https://esmocongress.esmo.orgWatch-and-wait (W&W) strategy for dostarlimab in localized deficient dMMR/MSI-H gastroesophageal adenocarcinoma (GEA): Results from the first interim analysis of the GERCOR-GONO DEWI phase II study
https://esmocongress.esmo.orgFOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study
https://esmocongress.esmo.orgDurvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma: ARION PRODIGE 67 randomized phase 2 trial
https://esmocongress.esmo.orgEfficacy of bemarituzumab in patients with advanced gastric and gastroesophageal junction cancer (GC/GEJ) by FGFR2 amplification status: Exploratory biomarker analysis from FORTITUDE-101 (F101) and FORTITUDE-102 (F102)
https://esmocongress.esmo.orgRandomised phase II study of mFOLFIRINOX ± SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial
https://esmocongress.esmo.orgSource: OncoDaily RT · x.com